Issue
Alert me when new journal issues are available via or via
2001: a transplant odyssey B.D. Kahan pages 3025-3026 Full Text | Full-Text PDF (42 KB)
Development of transplantation in Turkey M. Haberal pages 3027-3029 Full Text | Full-Text PDF (161 KB)
2001: a transplant odyssey opening speech T. Rosenberg pages 3030-3031 Full Text | Full-Text PDF (41 KB)
The matrix of clinical immunosuppression for transplantation B.D. Kahan pages 3035-3037 Full Text | Full-Text PDF (50 KB)
Achieving clinical transplant tolerance: what are the hurdles? A.D. Salamam, M.H. Sayegh pages 3038-3040 Full Text | Full-Text PDF (47 KB)
Death of alloreactive T cells sets the stage for immunoregulation to act X.C. Li, A.D. Wells, L.A. Turka, T.B. Strom pages 3041-3043 Full Text | Full-Text PDF (152 KB)
Allogeneic stem cells, clinical transplantation, and the origins of regenerative medicine T.B. Strom, L.J. Field, M. Ruediger pages 3044-3049 Full Text | Full-Text PDF (343 KB)
The present status of xenotransplantation G.A. Levy, A. Ghanekar, M. Mendicino, M.J. Phillips, D.R. Grant pages 3050-3052 Full Text | Full-Text PDF (50 KB)
Genetic modification for xenotransplantation: transgenics and clones A.J.F d’Apice, M.B Nottle, P.J Cowan pages 3053-3054 Full Text | Full-Text PDF (45 KB)
Mechanisms
FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines S Chen, K.B Bacon, G Garcia, R Liao, Z.K Pan, S.K Sullivan, H Nakano, A Matsuzawa, V Brinkmann, L Feng pages 3057-3063 Full Text | Full-Text PDF (261 KB)
The role of adhesion molecules and chemokines in homeostasis and pathologic processes in transplanted organs S.M. Stepkowski pages 3064-3066 Full Text | Full-Text PDF (54 KB)
Mechanism of action of the calcineurin inhibitors P.F. Halloran pages 3067-3069 Full Text | Full-Text PDF (51 KB)
TNF:TNF-R T-Cell costimulatory pathways in transplantation A. Yamada, A.D. Salama, N. Najafian, H. Auchincloss, M.H. Sayegh pages 3070-3071 Full Text | Full-Text PDF (121 KB)
The IL2 pathway in clinical immunosuppression B. Nashan pages 3072-3074 Full Text | Full-Text PDF (52 KB)
The evolving role of tor inhibitors for individualizing posttransplant immunosuppression M.I. Lorber, G.P. Basadonna, A.L. Friedman, K.M. Lorber, M.J. Bia, R. Formica, J.D. Smith pages 3075-3077 Full Text | Full-Text PDF (54 KB)
FTY720: activator of chemotaxis
FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects V. Brinkmann, C. Wilt, C. Kristofic, Z. Nikolova, R.P. Hof, S. Chen, R. Albert, S. Cottens pages 3078-3080 Full Text | Full-Text PDF (96 KB)
FTY720: a new dimension in transplantation B.D. Kahan pages 3081-3083 Full Text | Full-Text PDF (58 KB)
T-cell apoptosis triggered by FTY720 via mitochondrial pathway M. Fujino, X.-K. Li, L. Guo, Y. Kitazawa, N. Funeshima, S. Fukuda, H. Kimura, T. Miyashita, T. Okuyama, T. Amano, S. Suzuki pages 3084-3085 Full Text | Full-Text PDF (101 KB)
Calcineurin antagonists: cyclosporine
The evolution of therapeutic drug monitoring of cyclosporine1 B.D. Kahan pages 3086-3088 Full Text | Full-Text PDF (51 KB)
C2: liver transplantation
Neoral C2 in liver transplant recipients G.A Levy pages 3089-3091 Full Text | Full-Text PDF (126 KB)
Benefits of cyclosporine microemulsion (Neoral) C2 monitoring are sustained at 1 year in de novo liver transplant recipients J.R. Lake, Neo-INT-06 Study Group pages 3092-3093 Full Text | Full-Text PDF (49 KB)
Neoral C2 monitoring in pediatric liver transplant recipients S. Dunn, K. Falkenstein, G. Cooney pages 3094-3095 Full Text | Full-Text PDF (46 KB)
Efficacy of C2 monitoring of cyclosporine neoral in adult liver transplantation: a comparative study J. Santoyo, M.A. Suarez, J.A. Perez-Daga, J.L. Fernández Aguilar, J. Rodrigo, M. Jiménez, J.A. Bondia, A. De la Fuente pages 3096-3097 Full Text | Full-Text PDF (46 KB)
Optimization of cyclosporine exposure utilizing C2 level monitoring in de novo renal transplant recipients: the toronto general hospital experience N. Maham, C. Cardella, D. Cattran, S. Fenton, C. O’Grady, J. Hamill, R. Smith, E. Cole, Multi-Organ Transplant Program pages 3098-3099 Full Text | Full-Text PDF (49 KB)
Feasibility of changing therapeutic cyclosporine monitoring from C0 to C2 in stable renal recipients: narrower coefficient of variation with C2 monitoring S.-C. Chueh, C.-H. Liao, C.-J. Chang, M.-K. Lai pages 3100-3101 Full Text | Full-Text PDF (55 KB)
Optimizing neoral therapeutic drug monitoring with cyclosporine trough (C0) and C2 concentrations in stable renal allograft recipients G Einecke, I Mai, F Diekmann, L Fritsche, T Boehler, H.-H Neumayer, K Budde pages 3102-3103 Full Text | Full-Text PDF (49 KB)
Neoral drug monitoring in stable kidney allotransplant recipients: C0 versus C2 J. Lukaschek, J. Hofmann, D. Aerne, P. Ambühl, T. Kistler, A. Knoflach, P. Pei, U. Binswanger pages 3104-3105 Full Text | Full-Text PDF (77 KB)
Neoral dose monitoring with cyclosporine 2-hour postdose levels (C2) in different renal transplant patient age groups A. Rosati, E. Bertoni, M. Zanazzi, L. Di Maria, R. Ciuti, R. Piperno, L. Moscarelli, M. Biagini, M. Salvadori pages 3106-3107 Full Text | Full-Text PDF (49 KB)
Comparison of trough level and C2 cyclosporine blood concentration monitoring in outpatient kidney transplant recipients F. Braun, V.W. Armstrong, T. Lorf, R. Canelo, C. Arndt, M. Oellerich, B. Ringe pages 3108-3109 Full Text | Full-Text PDF (64 KB)
Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index L Hortal, A Fernández, A Losada, M Lorenzo, E Baamonde, C Plaza, R Gallego, N Vega, L Palop pages 3110-3111 Full Text | Full-Text PDF (44 KB)
Single-center study utilizing C2 level as monitoring tool in de novo renal transplant recipients treated with neoral M. Keshavamurthy, I. Al Ahmadi, S. Mohammed Raza, R. Baynton, K. Al Meshari, K. Al Shaibani pages 3112-3114 Full Text | Full-Text PDF (83 KB)
Heart transplantation
C2 blood levels in heart-transplanted patients immunosuppressed on a trough level-;based regimen R. Fiocchi, L. Iamele, L. Torre, C. Papageorgiou, A. Gamba, P. Ferrazzi pages 3115-3116 Full Text | Full-Text PDF (64 KB)
Other single time points
Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling? F. Gaspari, R. Caruso, D. Cattaneo, N. Perico, G. Remuzzi pages 3117-3119 Full Text | Full-Text PDF (54 KB)
Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity? J. Domı́nguez, A. Tomic, R. Norambuena pages 3120-3121 Full Text | Full-Text PDF (52 KB)
Cyclosporine A: peak or trough level monitoring in renal transplant recipients? R. Wacke, B. Drewelow, G. Kundt, E.-M. Hehl, R. Bast, H. Seiter pages 3122-3123 Full Text | Full-Text PDF (55 KB)
Cyclosporine level: which single-point estimation of drug level is the best? R. Sharma, J. Kumar, M. Ahmed, A. Gupta, S. Gulati, A.P. Sharma, M. Bhandari pages 3124-3125 Full Text | Full-Text PDF (43 KB)
Absorption AUC
Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients M. Wigger, E. Drückler, J. Muscheites, H.J. Stolpe, G. Kundt, R. Wacke pages 3126-3127 Full Text | Full-Text PDF (56 KB)
Usefulness of two-point AUC0–4 monitoring in maintenance renal transplant patients K Uchida, Y Tominaga, T Haba, A Katayama, T Sato, S Matsuoka, N Goto, T Kimata, A Takeda, K Morozumi, H Takagi, T Kobayashi, I Yokoyama, A Nakao pages 3128-3130 Full Text | Full-Text PDF (65 KB)
Initial neoral use for living-related partial liver transplantation: Its indication and limitation I. Yokoyama, T. Kobayashi, T. Nagasaka, D.-G. Liu, K. Uchida, A. Nakao pages 3131-3132 Full Text | Full-Text PDF (40 KB)
Abbreviated AUC measurements
C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients F Citterio, M.C Scatà, M.T Borzi, U Pozzetto, M Castagneto pages 3133-3136 Full Text | Full-Text PDF (56 KB)
Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice A Vathsala, Y.M Lu pages 3137-3139 Full Text | Full-Text PDF (54 KB)
Pharmacokinetics
Can three-times-a-aay cyclosporine neoral avoid cylosporine toxicity in renal transplant recipients? a pharmacokinetic study N. Swart, J. Botha, V. Tandon, P. Michaels, A.R. Pontin, J. Halkett, M.D. Pascoe, D. Kahn pages 3140-3141 Full Text | Full-Text PDF (41 KB)
Cyclosporine neoral profiling in japanese renal transplant recipients A Aikawa, K Arai, E Tajima, T Kawamura, H Ogiwara, K Sakai, S Mizuiri, T Ohara, A Hasegawa, T Kosugi, A Kusano, K Matsuo, M Obayashi, M Kurokawa pages 3142-3145 Full Text | Full-Text PDF (246 KB)
Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from sandimmune to neoral in stable renal transplant patients K Yoshida, T Kimura, Y Hamada, T Saito, T Endo, S Baba, S Shimada pages 3146-3147 Full Text | Full-Text PDF (44 KB)
Pharmacokinetic/pharmacodynamic relations
Pharmacodynamic monitoring of lymphocyte proliferation and TGF-β1 expression at cyclosporine a (CyA) trough levels (C0) and 2 hours after intake (C2) of CyA in human renal allograft recipients T. Böhler, K. Budde, M. Schneider, S. Eliazyfer, K. Dell, G. Einecke, F. Diekmann, L. Fritsche, I. Mai, H.H. Neumayer, J. Waiser pages 3148-3150 Full Text | Full-Text PDF (98 KB)
Cyclosporine dose fractioning might affect renal function in stable heart transplanted patients M. Baraldo, F. Pea, D. Poz, M.C. Albanese, U. Livi, M. Furlanut pages 3151-3153 Full Text | Full-Text PDF (84 KB)
Intestinal biotransformation of cyclosporine A in an extracorporeal pig intestine perfusion model F Braun, M Kassuhn, S Laabs, F Streit, V.W Armstrong, M Oellerich, B Ringe pages 3154-3155 Full Text | Full-Text PDF (79 KB)
Decreasing side effects of neoral through three-times-a-day protocol in chinese renal transplant patients Z.S Chen, F.J Zeng, Z.B Lin, Z.K Chen, B Sha, Z.X Wen, C.S Ming, W.J Zhang, S.S Xia pages 3156-3157 Full Text | Full-Text PDF (46 KB)
Tacrolimus
The development of tacrolimus in renal transplantation R. Shapiro pages 3158-3160 Full Text | Full-Text PDF (44 KB)
Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients C. Blume, M. Hollenbeck, K. Ivens, P. Heering, G.R. Hetzel, B. Grabensee pages 3161-3163 Full Text | Full-Text PDF (52 KB)
Optimal time for determination of blood tacrolimus level K.A. Jørgensen, J.V. Povlsen, J.H. Poulsen pages 3164-3165 Full Text | Full-Text PDF (57 KB)
Conversion from tacrolimus to neoral in liver and kidney transplant recipients R Ott, M Bussenius-Kammerer, D Scholz, R Neuhaus, R.H Tolba, L Fricke, V Müller pages 3166-3168 Full Text | Full-Text PDF (50 KB)
Anti-IL-2R monoclonal antibodies
Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens F Vincenti pages 3169-3171 Full Text | Full-Text PDF (48 KB)
Pharmacokinetics: basiliximab
Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients J.M Kovarik, A Korn, L Chodoff pages 3172-3173 Full Text | Full-Text PDF (88 KB)
Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients T. Haba, K. Uchida, A. Katayama, Y. Tominaga, T. Sato, I. Watanabe, H. Inagaki, T. Kimata, K. Goto, K. Morozumi, A. Takeda, S. Takahara, K. Takahashi, S. Oshima pages 3174-3175 Full Text | Full-Text PDF (69 KB)
Clinical outcomes
Anti-CD25 prophylaxis allows steroid free kidney transplantation W. Weimar, I.C. van Riemsdijk, P.J.H. Smak Gregoor, T. van Gelder pages 3176-3177 Full Text | Full-Text PDF (46 KB)
A single center experience with basiliximab induction therapy in renal transplantation M.L. Henry, R.P. Pelletier, E.A. Elkhammas, G.L. Bumgardner, R.M. Ferguson pages 3178-3179 Full Text | Full-Text PDF (42 KB)
Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates P.D Acott, J Lawen, S Lee, J.F.S Crocker pages 3180-3183 Full Text | Full-Text PDF (61 KB)
Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression J.N Boletis, H Theodoropoulou, T Hiras, D Stamatiadis, M Darema, E Psimenou, C Stathakis, A Kostakis pages 3184-3186 Full Text | Full-Text PDF (51 KB)
Pharmacoeconomic evaluation of simulect prophylaxis in renal transplant recipients S.J Walters, M Whitfield, R.L Akehurst, J.B Chilcott pages 3187-3191 Full Text | Full-Text PDF (63 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
